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High fat dietG protein-coupled receptor kinase 2 (GRK2) has recently emerged as a negative modulator of insulin signaling.
GRK2 downregulation improves insulin sensitivity and prevents systemic insulin resistance. Cardiac GRK2 levels
are increased in human heart failure, while genetically inhibiting GRK2 leads to cardioprotection in mice. How-
ever, themolecular basis underlying the deleterious effects of GRK2 up-regulation and the beneﬁcial effects of its
inhibition in the heart are not fully understood. Therefore, we have explored the interconnections among a sys-
temic insulin resistant status, GRK2 dosage and cardiac insulin sensitivity in adult (9 month-old) animals.
GRK2+/−mice display enhanced cardiac insulin sensitivity and mild heart hypertrophy with preserved systolic
function. Cardiac gene expression is reprogrammed in these animals, with increased expression of genes related
to physiological hypertrophy, while the expression of genes related to pathological hypertrophy or to diabetes/
obesity co-morbidities is repressed. Notably, we ﬁnd that cardiac GRK2 levels increase in situations where
insulin resistance develops, such as in ob/obmice or after high fat diet feeding. Our data suggest that GRK2down-
regulation/inhibition can help maintain cardiac function in the face of co-morbidities such as insulin resistance,
diabetes or obesity by sustaining insulin sensitivity and promoting a gene expression reprogramming that con-
fers cardioprotection.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
G protein-coupled receptor kinases (GRKs) were initially identiﬁed
as serine–threonine kinases able to phosphorylate agonist-activated G
protein-coupled receptors (GPCRs), triggering the binding of arrestinsK2, G protein-coupled receptor
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urga@cbm.uam.es (C. Murga).to the receptor, which impairs G protein coupling in a process known
as desensitization [1]. However, very recent ﬁndings suggest that the
GRK2 isoform is also a key controller of insulin receptor signaling [2].
GRK2 downregulation can prevent the development of metabolic disor-
ders, modulating energy expenditure and brown fat function [3] and
also insulin actions in peripheral tissues [2]. Notably, GRK2+/− mice
(expressing 50% less protein than control littermates) show improved
systemic insulin sensitivity, display enhanced activation of the insulin-
mediated Akt pathway inmuscle, adipose tissue and liver, and are resis-
tant to the induction of insulin resistance (IR) in three different mouse
models of this condition [2]. Remarkably, such differences in insulin
sensitivity between wild type (WT) and GRK2 hemizygous mice were
noted in the adult stage but were not evident in young animals [2].
GRK2 has also been described to play a relevant role in cardiovascular
physiopathology. Increased cardiac GRK2 levels have been reported in
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chemia, hypertension, volume overload and left ventricular hypertrophy
[1,4,5]. Also, enhanced GRK2 expression induced by neurohormonal
activation has been associated with lower cardiac function and poorer
prognosis in human heart failure (HF) and appears as an early event in
maladaptive cardiac remodeling in HF [5–7], altogether putting forward
GRK2 as a relevant therapeutic target in this myocardial disease
(reviewed in ref. [6]). Consistently, genetic inhibition of GRK2 is
cardioprotective in different animal models ([1,5–8] and the references
therein), and hemizygous GRK2 mice are hyper-responsive to catechol-
amines and display enhanced cardiac contractility and function, whereas
transgenic mice overexpressing different levels of this kinase show an
impaired adrenergic cardiac response [9]. However, the detailed molec-
ular mechanisms and the relevant functional interactions underlying
the deleterious effects of elevated GRK2 levels in cardiac function and
the beneﬁcial effects of its inhibition remain to be fully established.
In principle, up-regulation of GRK2 in HF would further exacerbate
the marked β-adrenergic desensitization observed in such condition.
However, chronic adrenergic activation appears to bemore detrimental
than beneﬁcial for heart disease and, most importantly, β-blockers
represent a successful standard treatment for this disease. In this
context, the fact that GRK2 inhibition acts in a synergic manner with
established β-blocker treatments (reviewed in [6,7]) suggests that
these two therapeutic strategies must have independent mechanisms
of action. Thus, the functional impact of altered GRK2 levels might also
be related to the interactions of this protein with cellular partners
other than β-adrenergic receptors [10].
In this regard, adding to the data showing that GRK2 up-regulation
inhibits insulin signaling in muscle or adipose tissue [2], recent ﬁndings
have suggested that cardiac-speciﬁc overexpression of GRK2 inhibits
glucose uptake and promotes IR after myocardial ischemia in young
mice [11]. However, the potential interconnections among a systemic
IR status, GRK2 levels and the cardiac maladaptive remodeling linked
to cardiac dysfunction have not been addressed to date.
In this report, we have characterized the activation of insulin signal-
ing pathways, tissue remodeling in the heart and cardioprotective gene
expression patterns in young and adultWT and GRK2+/−mice. This ex-
perimental model allows us to explore the consequences of a chronic,
physiological-range change in GRK2 levels with age (a risk factor for
the onset of most cardiovascular pathologies) that would mimic the
long sought pharmacological systemic inhibition of GRK2 as a potential
drug target. In addition, we have investigated the effect of systemic
IR-promoting conditions on cardiac GRK2 levels and its impact on
cardiac insulin responses. Our data point at new molecular links be-
tween GRK2 up-regulation in IR-related situations and maladaptive
cardiac remodeling in the adult mouse heart.
2. Materials and methods
2.1. Animals
Experiments were performed on male wild type and hemizygous-
GRK2 (GRK2+/−)micemaintained on the hybrid 129/SvJ C57BL/6 back-
ground. The animals were bred and housed on a 12-hour light/dark
cycle with free access to food and water. GRK2+/− mice, as well as
male leptin-deﬁcient obese ob/ob mice (C57BL/6J-Lepob/Lepob) and
their corresponding wild types (C57BL/6J, The Jackson Laboratory, Bar
Harbor, ME, USA)were fed ad libitum since weaning on either a normal
chow diet (providing 13% of total calories as fat, 67% as carbohydrate
and 20% as protein; 2014S Rodent Maintenance Diet, Teklad, Harlan,
Barcelona, Spain) or a high fat diet (providing 45% of total calories as
fat, 35% as carbohydrate and 20% as protein, Rodent Diet D12451,
Research Diets, New Brunswick, NJ, USA). Animals were maintained at
a room temperature of 22 ± 2 °C on a 12:12 light–dark cycle (lights
on at 08:00 am) with a relative humidity of 50 ± 10% and under
pathogen-free conditions. All animal experimentation proceduresconformed to the EuropeanGuidelines for the Care andUse of Laborato-
ry Animals (Directive 86/609) and approved by the Ethical Committees
for Animal Experimentation of the Universidad Autonoma de Madrid
and the University of Navarra (protocols 013/08 and 041/08).
2.2. Plasmamembrane preparation andGLUT4 translocation quantiﬁcation
Relative quantiﬁcation of GLUT4 protein in the plasma membrane
fraction was achieved by a subcellular fractionation method modiﬁed
from Rett K. et al. [12]. Mice were injected intravenously in the tail
vein with insulin (1 unit/kg of body weight). After 25 min, mice were
sacriﬁced by cervical dislocation and hearts were homogenized using
metal beads in a Tissue Lyser using cooled buffer (200 mM Tris–HCl
pH 7.5, 10 mM EDTA, 255 mM Sucrose) with protease inhibitors
(100 μM PMSF, 1 μM benzamidine, 10 μg/ml STI, 16 μU aprotinin,
10 μg/ml bacitracin). Lysates were centrifuged at 9000 ×g for 20 min.
The pellet (P1) was resuspended in buffer, homogenized again and
centrifuged at 200 ×g for 20 min. The plasma membrane-enriched P2
was then resuspended and homogenized in RIPA buffer (100 mM
Tris–HCl pH 7.4, 600 mM NaCl, 2% Triton X-100, 0.2% sodium dodecyl
sulfate, 1% deoxycholate plus protease inhibitors) for Western Blot
analysis. Protein content was quantiﬁed using the Lowry procedure
and 40 μg of total protein was resolved on a 12% SDS-PAGE gel and
transferred to a nitrocellulose membrane. Blots shown here were
probed with speciﬁc antibodies against GLUT4 (EMD Millipore,
Darmstadt, Germany), Caveolin 3 (BD Transduction Laboratories,
Franklin Lakes, NJ, USA) and α-Tubulin (Santa Cruz Biotechnology,
Dallas, TX, USA).
2.3. Insulin treatments and Western Blots
Insulin (Actrapid®, Novo Nordisk, Bagsvaerd, Denmark) solution in
saline serum (1 unit/kg body weight) was administered by tail vein in-
jection for acute cardiac insulin pathway activation analysis. After either
3 or 5 min, mice were sacriﬁced by cervical dislocation and hearts were
quickly collected, washed and frozen at−70 °C. Heart tissue was ho-
mogenized using metal beads in a Tissue Lyser using hypotonic buffer
(20mMTris–HCl pH 7.5, 1mMEDTA, 1mMEGTA) completedwith pro-
tease and phosphatase inhibitors (100 μM PMSF, 1 μM benzamidine,
10 μg/ml STI, 16 μU aprotinin, 10 μg/ml bacitracin and Phosphatase In-
hibitor Cocktail—PhosSTOP (Roche, Indianapolis, IN, USA)—following
manufacturer's protocol). Then 0.1% (v/v) Triton X-100 was added and
the samples were agitated for 1 h at 4 °C, and centrifuged to measure
supernatant protein content using the Lowry procedure. For Western
Blot analysis, typically 40 μg of total cardiac protein was resolved per
lane on a 7.5% SDS-PAGE gel and transferred to a nitrocellulose mem-
brane. Blots were probed with speciﬁc antibodies against phospho-Akt
(Ser473), Akt, phospho-p70S6K (Thr389), phospho-ERK1/2 (Thr202/
Tyr204) (Cell Signaling Technology, Beverly, Ma, USA), p70S6K,
phospho-IRS1 (Tyr896) (BD Biosciences, Franklin Lakes, NJ, USA),
ERK-1, ERK-2, GRK2, Nucleolin (Santa Cruz Biotechnology, Dallas, TX,
USA), GAPDH (Abcam, Cambridge, UK) and IRS1-PH (kindly provided
by Deborah J. Burks, Spain) [13].
2.4. Cardiac morphometry
For the histological and morphometric analysis of the hearts, mice
were anesthetized with isoﬂurane and an intracardiac injection of cold
KCl solution was used to stop the heart in diastole before the heart col-
lection. Hearts were weighted for cardiac index determination, and the
medial section was ﬁxed in formaldehyde and embedded in parafﬁn
prior to transversal sectioning using a microtome. Masson's Trichrome
staining was performed for the morphometric analysis and Syrius red
staining for ﬁbrosis quantiﬁcation. Images were analyzed using the
AnalySIS® software (Soft Imaging System).
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Tomeasure global systolic cardiac function and left ventricular mass
(LVM), echocardiographywas performed in 9month-oldWT and hemi-
zygous GRK2mice. Mice were anesthetized by inhalation of isoﬂurane/
oxygen (1.25%/98.75%) and examined by a 30 MHz transthoracic
echocardiography probe. Images were obtained with Vevo 770
(VisualSonics, Toronto, Canada). The internal diameter of the LV was
measured in the short-axis view from M-mode recordings in end
diastole and end systole and ejection fraction (EF) and fractional
shortening (FS) were calculated using the formulas as previously
described [14].
2.6. RNA isolation and microarray analysis
mRNA from frozen heart tissue was extracted using metal beads
(2 min, 30 Hz) in a Tissue Lyser and Fibrous Tissue RNeasy Mini Kit,
both from QIAGEN (Hilden, Germany). Three mice per condition were
used for the gene expression proﬁle analysis of GRK2+/− and WT mice
of 4 and 9 months of age. cDNA synthesis, labeling andmicroarray anal-
ysis were performed with the aid of the Bioinformatics group at the
National Center of Biotechnology (CNB, Madrid, Spain). Generation of
double-stranded cDNA, preparation and labeling of cRNA, hybridization
to GeneChip® Mouse Genome 430 2.0 Arrays (Affymetrix, Santa Clara,
CA, USA) and washing were performed according to the protocol
provided by Affymetrix. Probe sets were summarized using the
LiMMA algorithm. Results were analyzed and visualized using
Researcher's Digest software and FIESTA viewer respectively, as well
as Multiexperiment Viewer software (TM4 Microarray Software Suite).
2.7. Co-immunoprecipitation assays
Cell lysates obtained as previously described for Western Blot were
quantiﬁed using the Lowry procedure. Next, 500 μg total protein per ly-
sate was incubated with 10 μl of either rabbit IgG or IRS1 antibody
(Santa Cruz Biotechnology, Dallas, TX, USA) and 0.4 μg/μl BSA on a rotat-
ing shaker at 4 °C overnight and 15 μl of Protein G-Sepharose (50% in
lysis buffer) were added to each tube. After 2 h on a rotating shaker at
4 °C, tubes were centrifuged at 14,000 ×g for 5 s and the pellets
were washed with pre-chilled washing buffer (hypotonic-1% Triton)
for 10 times (1ml each). Pelletswere then boiled in 4× Laemmli loading
buffer for 5 min and used for Western Blot analysis. Blots were probed
with speciﬁc antibodies against IRS1-PH [13] and GRK2 (Santa Cruz
Biotechnology, Dallas, TX, USA).
2.8. RT-PCR and microarray validation
mRNA from heart tissue of at least 6 WT and 6 GRK2+/−mice was
isolated as described before. RT-PCRs were performed by the Genomic
Facility at CBMSO using Light Cycler equipment (Roche, Indianapolis,
IN, USA). Microarray validations were performed using both commer-
cial Taqman Gene Expression Assay probes (Applied Biosystems, Life
Technologies, Grand Island, NY, USA) and self-designed probes pur-
chased from Sigma with Syber Green technology. qPCRs and statistical
analysis of the data were performed by the Genomic Facility at CBMSO
using GenEx software.
2.9. Small-animal PET protocol
2-Deoxy-2-[18F]-ﬂuoro-D-glucose in isotonic saline solution was
injected through the intravenous catheter of WT and GRK2+/− adult
mice to characterize heart glucose utilization in basal and after 5-min
insulin stimulation. 90-minute dynamic imaging was performed with
a piPET scanner and tomographic images were reconstructed using a
three-dimensional ordered subset expectation maximization algorithm
as previously described [15]. Region of interest measurements weremade on multiple axial slices of the myocardium and tracer uptake
was quantiﬁed as standardized uptake values normalized by injected
dose and corrected for body weight.2.10. Statistics
Data were analyzed by one-way ANOVA, followed by Bonferroni's
post hoc analysis, or by unpaired T-testing when speciﬁed, as appropri-
ate. For all tests, p b 0.05 was considered statistically signiﬁcant
after Bonferroni corrections, if needed, and all data are reported as
means ± SEM.3. Results
3.1. Decreased GRK2 levels correlate with enhanced cardiac insulin
sensitivity
GRK2 can act as a negative modulator of insulin receptor signaling
pathways, and adult GRK2+/− mice show improved systemic insulin
sensitivity and are resistant to the induction of IR in peripheral tissues
[2]. In this context, we explored the possibility that GRK2 dosage
could modify heart insulin sensitivity in vivo in 9 month-old mice. The
translocation to theplasmamembrane of theGLUT4 glucose transporter
is a key early event in glucose uptake stimulated by insulin. As can be
observed in Fig. 1a, insulin-dependent GLUT4 translocation was signiﬁ-
cantly enhanced in adult GRK2 hemizygous mice, compared to wild-
type animals, as assessed by Western Blot analysis of membrane frac-
tions of cardiac tissue. These results are in agreementwith the increased
accumulation of labeled deoxyglucose in the hearts of GRK2+/− mice
quantiﬁed by PET (Supplementary Fig. 1S). A similar pattern was ob-
served for the rapid stimulation of Akt and its downstream target
p70S6K kinase detected with speciﬁc phospho-antibodies upon injec-
tion of insulin (Fig. 1b–e).
Of note, upstream insulin signaling events such as the amount of
phospho-Tyrosine(Tyr896)IRS1 were increased in GRK2+/− hearts
after insulin stimulation while the activation status of the ERK cascade
was not affected (Supplementary Fig. 1Sb–d). Together, these results
demonstrate that the metabolic and pro-survival signals downstream
of insulin were more potently activated in GRK2+/− hearts than in WT
mice.3.2. GRK2+/− 9 month-old mice display mild, non-pathological heart
hypertrophy
Themodulation of the PI3K/Akt and the ERK pathways in the heart is
shared by insulin, IGF-1 and hypertrophic agonists such as angiotensin
II. The PI3K/Akt cascade relates mostly to physiological hypertrophy,
whereasMAPK signaling, together with PKC and calcineurin/NFAT, par-
ticipates in the development of the pathological hypertrophy typically
induced by angiotensin II (reviewed in ref. [16]).
We found that GRK2+/−mice showed a modest but signiﬁcant in-
crease in heart to body weight ratio and in the total cardiac area with
age compared to the change observed in WT animals (Fig. 2a and b).
We also found an enhanced increase in cardiomyocyte diameter in
GRK2+/− animals (Fig. 2c), an established indicator of cardiac hypertro-
phy. No differences in these parameters were found at 4 months of age
betweenWT and GRK2+/− animals. Echocardiographic analysis also re-
vealed a certain degree of hypertrophy in the 9 month-old hemizygous
mice, mainly referred to left ventricular mass (data not shown) in the
absence of any alterations in cardiac functionality, as deﬁned by frac-
tional ejection (EF) or fractional shortening (FS) parameters (Fig. 2d).
Consistently, ﬁbrosis was not increased in either 4 or 9 month-old
GRK2+/−mice compared with age-matched controls (Fig. 2e).
Fig. 1. GLUT4 translocation to themembrane and insulin signaling are upregulated in hearts from adult GRK2+/−mice. a). GLUT4 translocation in the plasmamembrane fraction after an
intravenous injection of insulin for 25min in 9month-oldWT and GRK2+/−mice (N=6–8 per genotype). Resultswere normalized to Caveolin 3 levels and are expressed as fold increase
over basal (non-insulin treatedmice). Representative blots are shown includingα-Tubulin blot as an indicator of the absence of cytosolic contamination. Quantiﬁcation of Akt phosphor-
ylation (Ser473) (b) and p70S6K phosphorylation (Thr389) (c) in the cardiac tissue lysates of WT or GRK2+/− 9 month-old mice after an intravenous injection of insulin for 3 or 5 min
(N= 3–5). Results are expressed as fold increase over control (non-insulin treatedmice). d) Representative Western Blots of the speciﬁed phospho-proteins and controls in heart tissue
3 or 5 min after insulin injection. Data are mean ± SEM of the indicated independent experiments. ***p b 0.001; *p b 0.05.
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involved in physiological hypertrophy/cardioprotection
Insulin is known to play a protective role in cardiac physiology, via
the control of cardiac substrate utilization, cardiomyocyte growth, gene
expression, survival and contractility by means of the homeostatic stim-
ulation of the PI3K/Akt and other intracellular signaling pathways [17].
As an unbiased approach to assess the functional consequences of alter-
ing GRK2 levels in themodulation of insulin response and heart function,
we compared the transcriptional proﬁle of the cardiac tissue of WT and
GRK2+/−mice of 4 or 9 months of age usingmicroarray RNA expression
techniqueswithout subjecting the animals to prior speciﬁc treatments to
study the integrated response of the tissue to homeostatic endogenous
signals. Comparison of gene expression proﬁles between WT and
GRK2+/− animals at each group of age (database access number
GSE41706) revealed signiﬁcant differences only at 9 months (33 genes
signiﬁcantly up-regulated and 28 genes down-regulated in GRK2+/−
mice compared to WT) while no differences between genotypes were
detected at 4 months of age (Fig. 3a and Supplementary Table 1),suggesting that the effects of GRK2 dosage on cardiac gene expression
require additional age-related changes to become apparent.
We next performed a detailed analysis of the function and character-
istics of the up or down-regulated genes. Several interesting patterns
were noted. First, GRK2+/−mice at 9 months of age showed decreased
expression of genes described to be up-regulated during pathological
heart hypertrophy and/or in well-characterized cardiovascular disease
co-morbidities such as diabetes and obesity. Eight out of the 28 genes
down-regulated in GRK2+/− mice (29%) belonged to this group (see
Fig. 3b). This list included the pivotal heart hypertrophy marker Acta1
(skeletal muscle alpha-actin) and the atrial natriuretic factor precursor
Nppa [18,19]; the cardiovascular heat shock protein Hspb7, with high
expression in ob/ob mice skeletal muscle [20] and polymorphisms
associated with development of idiopathic dilated cardiomyopathy
and heart failure [21]; the transcription factor promyelocytic zinc ﬁnger
protein (Plzf, also known as Zbtb16), a mediator of angiotensin 2-type 2
receptor-triggered cardiac hypertrophy [22]; the microﬁbril-associated
glycoprotein-2 (Magp-2, also known asMfap5), an angiogenic stimula-
tor upregulated in transgenic models of HF [23], or the tissue inhibitor
Fig. 2.GRK2+/− 9month-oldmice showmild, non-pathological heart hypertrophy. a) Heartweight (mg) to bodyweight (g) ratio in 4 and 9month-oldWT and GRK2+/−mice (N= 7–14).
b) Total area of cross sections of each heart was measured from high-resolution images using the AnalySIS® software and expressed in mm2 forWT (white bars) and GRK2+/− (black bars)
mice (N = 5–9). c) Cardiomyocyte diameter (in μm) was measured in the cross-section of cells perpendicular to the slices stained with Masson's Trichrome in at least 20 cells per sample
using the AnalySIS® software (N = 5–9). d) Fold change of ejection fraction (EF) and fractional shortening (FS), with statistical analysis performed using T-test. e) Quantiﬁcation of the
ﬁbrotic area of heart cross sections stained with Syrius red, digitalized using the Axiovision software and analyzed using the AnalySIS® software. Representative pictures are shown when
applicable. Data are mean ± SEM of the indicated independent experiments. *p b 0.05.
Fig. 3. Comparison of cardiac gene expression proﬁles between young (4 month-old) or adult (9 month-old)WT and GRK2+/−mice. a) Genes whose expression varied signiﬁcantly be-
tweenWT andGRK2+/−mice are represented. Pairwise analyseswere performed and visualized using the FIESTA viewer for an FDR b 0.2 (fold change N 1.5 or≤1.5). No geneswere found
to change signiﬁcantly at 4 months of age, but, at 9 months of age, 61 genes were signiﬁcantly different betweenWT and GRK2+/−mice. Black, genes whose expression is increased in
GRK2+/− vsWT. Gray, genes whose expression is reduced in GRK2+/− vsWT. b) The table depicts genes reported to be upregulated during pathological heart hypertrophy or during co-
morbidities such as diabetes/obesity (see references in the text) found to be downregulated in adult GRK2+/−mice vs WT heart microarray, or genes for which the inverse relationship
occurs (left panel). Also, a list of genes upregulated/downregulated in the array and also during physiological heart hypertrophy or response to exercise is speciﬁed (right panel).
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remodeling and deteriorating HF [24]. Prostaglandin D synthase
(Ptgds), increased in the coronary circulation of angina patients [25]
and overexpressed in type 2 diabetes [26] and the p85 alpha PI3K regu-
latory subunit (Pik3R1), enhanced in the myocardium of mice develop-
ing diet-induced obesity [27] and a key negative regulator of insulin
signaling [28,29] were also decreased in 9 month-old GRK2+/− hearts.
A second interesting pattern found in GRK2+/−micewas that 10 out
of 33 genes thatwere up-regulated in these animals (30%)have been re-
ported to play a protective role in cardiovascular disease and are often
down-regulated in pathological heart hypertrophy and/or diabetes/
obesity co-morbidities (Fig. 3b). In this regard, the expression of
Ppargc1b, Hdac9, RRad, or Pde4b, reported as key negative regulators of
pathological heart hypertrophy, was enhanced in GRK2+/− mice.
PGC1beta (peroxisome proliferator-activated receptor (PPAR)-
gamma1beta co-activator) is essential for mitochondrial biogenesis
and energy homeostasis. Decreased Ppargc1b expression correlates
with cardiac insufﬁciency and cardiomyopathy and with obesity and
type-2 diabetes, whereas its genetic deletion accelerates the transition
to HF following pressure overload hypertrophy [30,31]. HDAC9 is an in-
hibitor of pathological (but not physiological) cardiac hypertrophy and
Hdac9-deﬁcient mice exhibit stress-dependent cardiomegaly [32].
RRAD (Ras associated with diabetes GTPase) levels are decreased in
human failing hearts and in animal and cellular models of cardiac hy-
pertrophy, and RRad-deﬁcient mice are more susceptible to this condi-
tion [33]. RRAD appears to prevent CAMK-II-dependent hypertrophy,
to inhibit cardiac ﬁbrosis and to modulate beta-adrenergic mediated
contractility [33,34]. Phosphodiesterase 4B (PDE4B) is an important,
protective negative modulator of beta-adrenergic-mediated contractili-
tywith decreased levels in cardiac hypertrophy [35]. Thrombospondin 1
(Thbs1), a protein that modulates extracellular matrix metabolism and
ﬁbroblast phenotype, suggested to act as a protective signal in the
stressed heart [36] was also enhanced in GRK2+/− mice, as was the
anti-angiogenic homeobox geneMeox2 [37].
The third relevant pattern of differential expression detected in
GRK2+/− mice reﬂects changes in the expression of genes similar to
those taking place upon exercise and in situations of physiological
heart hypertrophy (Fig. 3b). These include the up-regulation of the
central protective factors Ppargc1b and Nr4a1 (see above); the early re-
sponse genes FosB and Apold 1, reported to be enhanced in cardiac tissue
upon acute physical activity [38] and the downregulation of the tran-
scription factor C/EBPbeta (Cebpb), a member of the bHLH family. Im-
portantly, the latter has been recently identiﬁed as a master regulator
of physiological cardiac hypertrophy [39,40]. The mRNA expression of
C/EBPbeta is reduced circa 60% (in the same range of our data) in
mouse hearts in an exercise model allowing expression of an adaptive
gene proﬁle related to physiological hypertrophy, and mice with
reduced cardiac levels of this protein displayed resistance to cardiac
failure upon pressure overload [39]. The expression proﬁle of several
of the key genes supporting these patterns was validated by qPCR
(Supplementary Fig. 2S).
In sum, themicroarray analysis detected in GRK2+/−mice hearts an
increased expression of a limited group of important genes related to
physiological hypertrophy while the expression of genes key to the de-
velopment of pathological hypertrophy or related to diabetes/obesity
co-morbidities is repressed.
3.4. Increased cardiac GRK2 expression in adult obese (ob/ob) mice and in
high fat diet-fed animals
Since GRK2 levels increase in muscle and adipose tissue under insu-
lin resistance-promoting conditions [2] we tested whether this process
was also taking place in cardiac tissue. A clear increase in GRK2 protein
levelswas observed in hearts of 8month-old ob/obmice (Fig. 4a), an age
inwhich this strain ofmice is known tomanifest cardiac hypertrophy, IR
andmetabolic alterations involving alterations in the PI3K/Akt axis [41].This increase in total GRK2 protein levels caused an increment in the
amount of GRK2 that could be detected in association with IRS1
(Fig. 4b), a situation that we have previously described to negatively
modulate insulin signaling. GRK2 levels were also increased upon
feeding young animals a high fat diet (HFD, Fig. 4c), a well-established
trigger for systemic IR that can promote cardiac remodeling and dys-
function and known to disrupt the insulin-stimulated IRS1/PI3K/Akt
cascade [42]. This increase is similar to that observed in other insulin-
sensitive tissues [2], and also had as a consequence a larger amount of
formation of IRS1–GRK2 complexes (Fig. 4d). We investigated insulin
responses in cardiac tissue of WT and GRK2+/− HFD-fed animals.
Fig. 4e–f shows that sensitivity to insulin is compromised in WT hearts
after HFD feeding, while it is strongly preserved in GRK2+/− hearts, in
the absence of changes in insulin-induced ERK phosphorylation.
Together these results suggest that the increase in GRK2 protein levels
observed upon HFD feeding or genetically-induced obesity promotes
GRK2-dependent sequestration of IRS1 and provides a mechanistic ex-
planation for the IR state of cardiac tissue in both experimental
conditions.
4. Discussion
We have addressed herein the potential interconnections among an
IR status, GRK2 dosage and cardiac remodeling by investigating the im-
pact of GRK2 down-modulation on cardiac insulin sensitivity and gene
expression patterns, and the effects of systemic insulin resistance-
promoting conditions on cardiac GRK2 levels.
First, we ﬁnd that decreased GRK2 levels speciﬁcally preserve meta-
bolic and pro-survival signals downstream of insulin (such as the Akt/
p70S6K pathway and glucose transport) in the hearts of 9 month-old
GRK2+/− animals, whereas the ERK activation status is not affected.
Second, with age, GRK2 down-regulation triggers physiological heart
hypertrophy and switches on a cardioprotective gene expression pat-
tern as detected in such adult mice. This pattern is characterized by an
increased expression of a limited group of key genes related to physio-
logical hypertrophy, while the expression of genes reported to lead to
the development of pathological hypertrophy or related to diabetes/
obesity co-morbidities is repressed, compared to WT individuals.
Third, we uncover that cardiac GRK2 expression levels increase in situ-
ations of systemic insulin resistance, such as in obese mice or after HFD
feeding, conditions in which larger amounts of GRK2–IRS1 complexes
are formed. Fourth, while insulin resistance develops in the hearts of
wild-type mice after HFD feeding, sensitivity to insulin was strongly
preserved in GRK2+/− cardiac tissue.
We have previously reported that GRK2+/− mice are protected
against HFD-induced obesity and systemic IR, and we cannot rule out
that this global protectionmay contribute to the observed enhanced in-
sulin signaling in the heart upon a HFD. However, given the enhanced
interaction of GRK2 with IRS1 that we ﬁnd in cardiac tissue of different
obesemicemodels, our data point at an important role for this kinase in
negatively regulating insulin signaling in the heart, coherent with what
was previously published by Garcia-Guerra et al. [2] involving the
sequestration of IRS1 protein in GRK2 complexes thus impairing down-
stream signaling from the insulin receptor.
Previous reports have determined the importance of insulin
signaling in cardiac physiopathology [43]. In particular, results in
cardiomyocyte-speciﬁc deletion of the insulin receptor (CIRKO mice)
have revealed that insulin can control cardiac gene expression patterns
since loss of its receptor promotes a genomic reprogramming [44]. Insu-
lin signals also control the size of the heart and cardiomyocytes, and de-
letion of insulin receptor decreases cardiac size by 20–30% [45]. These
results are in agreement with the phenotype we ﬁnd in GRK2 hemizy-
gous mice in which the increased sensitivity for insulin signals results
in gene expression reprogramming and an increased cardiac size.
The fact that GRK2 downregulation potentiates the insulin-triggered
PI3K/Akt pathway in the adult mice heart is then consistent with the
Fig. 4. Expression of the GRK2 protein is increased in myocardial tissue of obese or high fat diet-fed mice which correlates with higher levels of IRS1/GRK2 complexes, whereas GRK2+/−
animals are resistant to high fat diet-induced insulin resistance in cardiac tissue. a) The expression levels of GRK2were analyzed byWestern Blot in cardiac tissue of 8month-old ob/ob or
WTmice and quantiﬁed by densitometry analysis. Resultswere normalized byGAPDHprotein levels and expressed as percent over control (WTmice) (N=5). b) Total protein fromheart
tissue (500 μg)was immunoprecipitatedwith the anti-IRS1 or anti-IgG antibodies, and the resulting immune complexeswere analyzedbyWestern Blotwith the corresponding antibodies
against GRK2 and IRS1 (N= 3). Precipitated GRK2 amount was normalized with immunoprecipitated IRS1 amount. Same for 3 month-old HFD-fed mice represented over standard diet-fed
animals in (c) and (d) (N=9). Representative blots are shown. Data aremean± SEMof the indicated independent experiments. **p b 0.01; *p b 0.05. e) RepresentativeWestern Blots of the
speciﬁed phospho-proteins and controls in heart tissue after 12 weeks of HFD feeding or SD and 3 min insulin injection in WT or GRK2+/−mice. f) Quantiﬁcation of Akt phosphorylation
(Ser473), p70S6Kphosphorylation (Thr389) or ERK1/2 phosphorylation (Thr202/Tyr204) in cardiac tissue lysates ofWT andGRK2+/−mice after 12 weeks ofHFD feeding after an intravenous
injection of insulin for 3 min (N= 3–4). Results are expressed as fold increase over basal (untreated mice). Statistical analysis was performed using T-test. Data are mean± SEM of the indi-
cated independent experiments. +++p b 0.001;+p b 0.05 referred to basal (untreatedmice); **p b 0.01; *p b 0.05 referred to fold increase upon insulin stimulation over HFD fedWTmice.
2454 E. Lucas et al. / Biochimica et Biophysica Acta 1842 (2014) 2448–2456mild hypertrophic phenotype conferred by age to GRK2+/− animals
being physiological rather than pathological, This is in agreement with
the morphometric analysis and functional results, and with an overall
cardio-protective gene expression pattern (decreased presence of path-
ological genes, enhanced expression of critical protective genes) in the
heart of GRK2+/− 9 month-old mice. It is worth noting that GRK2+/−
animals displayed changes in the expression of several genes reported
to be similarly modulated by insulin in the heart or other tissues
(Nr4a1, Tcﬂ2, Rrad, Aqp7, Cebpb, Ppargc1b, Egr1), and a relevant propor-
tion of genes whose expression is altered in hemizygous animals can be
related to: i) the modulation of insulin sensitivity; ii) the PI3K/Akt
pathway; and iii) diabetes/obesity-related pathological situations.
Insulin activation of the PI3K/Akt cascade is protective in the heart
by inhibiting apoptosis and oxidative stress [46], whereas myocardial
IR has been suggested as a key factor in the development of HF [47,
48]. In this context, our results strongly suggest the novel concept that
cardiac GRK2 levels could act as an integrative sensor of different path-
ological inputs and affect cardiac function by simultaneously altering
beta-adrenergic and insulin signaling (see suggested model in Fig. 5).
Thus, the increase in cardiac GRK2 levels previously reported to take
place in myocardial infarction or hypertension as a consequence of
excessive neurohormonal stimulation [5,6], would also take place as a
consequence of insulin resistance-promoting conditions such as a HFD
or obesity, by mechanisms that remain to be investigated. Also,
enhanced cardiac GRK2 would promote, in addition to the canonical ef-
fects described for GPCR signaling, an insulin-resistant state of the heartleading to alterations of key metabolic and cardioprotective pathways
[11], further fuelling a dysfunctional cycle and allowing progression to
maladaptive remodeling.
A detrimental vicious cycle has been postulated [48,49] in which the
compensatory hyper-adrenergic state characteristic of reduced cardiac
output would promote lipolysis in the adipose tissue. This would lead
to increased circulating levels of free fatty acids, which in turn would
inhibit cardiac glucose transport, switching energy substrate use and
triggering heart lipotoxicity. Conversely, many mechanisms have been
suggested to explain the increased incidence of HF in diabetic patients,
including hyperinsulinemia, hyperglycemia, lipotoxicity, obesity, vascu-
lar alterations, increased oxidative stress or hyperactivation of neurohu-
moral systems ([47,48,50] and the references therein). Our data suggest
that GRK2 could participate as an important integrative node in such
complex mechanisms linking HF, diabetes and IR.
Such central role of GRK2 also fosters its potential as a therapeutic
target and diagnostic marker. Our study suggests that strategies leading
to a systemic reduction in GRK2 levels/function, even when used in a
sustained temporal frame and in adult tissue, could facilitate the activa-
tion of deﬁned cardioprotective routes, such as the insulin pathway.
This would promote a physiological hypertrophy-like gene expression
pattern that could contribute to explain the beneﬁcial outcome of
GRK2 inhibition.
This discovery could help explain the reported reinforcement be-
tween the therapeutic effects of down-regulating cardiac adrenergic
input (using beta-blockers) and GRK2 down-modulation.
Fig. 5. Schematic representation of the proposed model of GRK2 up-regulation linking insulin-resistance and maladaptive cardiac remodeling. Increased GRK2 as a result of different
pathophysiological situations would lead to a decrease not only in β-AR responsiveness, but also in insulin signaling thus promoting a pathological increase in the neurohumoral
stimulation of the heart, and also lead to IR thus aggravating this condition. GRK2-promoted transcription reprogramming would also impinge upon both processes.
2455E. Lucas et al. / Biochimica et Biophysica Acta 1842 (2014) 2448–2456Since our data and previous report by other laboratories [1,6,7] indi-
cate that reduced GRK2 revels are beneﬁcial for cardiac function and
also for maintaining vascular tone [4], and systemic insulin sensitivity
[2], it could be argued that GRK2 hemizygosity would confer an overall
beneﬁt. However, the fact that a GRK2+/+ genotype has been positively
selected for by evolution suggests that the expression level generated by
such genotypemust be overall adaptative. Nevertheless, unlimited food
availability, a condition that humans nowadays share with caged ani-
mals, was not at all present during evolution and therefore this might
explain why GRK2 downregulation was not selected for.
GRK2 inhibition has been shown, in mouse models, to delay the re-
duction in glucose uptake and preserve insulin signaling in the heart
after myocardial ischemia [11] and to prevent the development of sys-
temic IR [2]. It is also worth noting that, apart from its catalytic kinase
activity (target for potential GRK2 inhibitors), GRK2 plays an important
functional role via protein–protein interactions. Our gene expression
data cannot dissect which biological function of GRK2 needs to be re-
duced for therapeutic purposes, and it could well be possible that inhi-
bition of the enzymatic activity of GRK2 might not reproduce the
beneﬁcial effects observed upon its under-expression. Thus, a better
knowledge of means to reduce GRK2 levels in vivo, such as increasing
its degradation rate or decreasing transcription, should be built before
an effective GRK2 downmodulation therapy can be designed. Interest-
ingly, ventricular assist device implantation, known to downregulate
GRK2 levels [51], also reverses IR and normalizes cardiac metabolism
in patients with advanced HF [52]. This is consistent with a beneﬁcial
role for GRK2 inhibition in this context. Notably, the reduction in
GRK2 protein levels observed in lymphocytes of HF patients after an
exercise-training program can predict long-term survival [53]. On the
other hand, enhanced GRK2 levels in peripheral lymphocytes mimic
myocardial levels during hypertension, myocardial ischemia and heart
failure [6] and are also increased in patients with metabolic syndrome
[2]. Therefore, it will be interesting to explore the potential use of
GRK2 as a prognostic cardiovascular risk marker when co-morbidities
such as diabetes, IR and obesity are present.
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